DeepLife
Jean Pascal Tranie has extensive experience in the biotechnology and investment sectors, serving as President of Aloe Private Equity since 2004, where emphasis is placed on biotech investments and co-founding three biotech companies. Tranie has also held significant positions including CEO in renewable energy investments in France, and as a Partner focused on cleantech investments across Europe and Asia. Currently, Tranie is a Board Member and preseed investor in several biotech firms including PepKon, Allogenica, POLYGON Therapeutics, DeepLife, and DiogenX, as well as a preseed investor in WhiteLab Genomics. Prior experience includes positions as President at Viventures Partners and CEO at Numericable. Tranie graduated from École Polytechnique between 1979 and 1982.
This person is not in any teams
DeepLife
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.